Dr. Anne Bassett is a senior scientist within the Schizophrenia Division and heads the Clinical Genetics Research Program at CAMH. She holds the Dalglish Chair in 22q11.2 Deletion Syndrome at the University of Toronto and University Health Network (UHN), is a senior scientist at the Toronto General Hospital Research Institute, and a professor in the University of Toronto Department of Psychiatry, with cross-appointments in the Division of Cardiology and the Department of Mental Health at UHN. She received the 2020 Lieber Prize for Outstanding Achievement in Schizophrenia Research from the Brain and Behavior Research Foundation, only the second Canadian to receive this honour.
Areas of Research
Dr. Bassett is an internationally renowned expert in the genetics of schizophrenia and other complex developmental disorders, including congenital cardiac disease. The goal is to gain new insights into the mechanisms of illness that will enable development of novel treatment and prevention strategies. She is the principal investigator of studies that aim to understand the genetic architecture of schizophrenia and characterize clinically relevant genetic subtypes of schizophrenia. Dr. Bassett has pioneered studies of the first molecular subtype of schizophrenia, known as 22q11.2 deletion syndrome. Dr. Bassett’s work has shown that up to one in 20 patients with schizophrenia has this or another relevant genetic change that may be found with a standard clinical blood test. As leader in Medical Psychiatry and translating genetic research findings directly into clinical practice, Dr. Bassett’s career embodies precision medicine, and includes teaching at all levels and extensive public service.
View Dr. Bassett's publications on PubMed.